公开(公告)号：US11426388B2

公开(公告)日：2022-08-30

申请号：US16460161

申请日：2019-07-02

申请人： Romark Laboratories L. C.

发明人： Jean-Francois Rossignol ,  Marc Ayers

IPC分类号： A61K31/426 ,  A61K9/24 ,  A61K9/28 ,  A61K31/7056 ,  A61K38/21 ,  A61K9/20 ,  A61K9/48

摘要： Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.

公开(公告)号：US10336058B2

公开(公告)日：2019-07-02

申请号：US15861234

申请日：2018-01-03

申请人： Romark Laboratories L. C.

发明人： Jean-Francois Rossignol

IPC分类号： A61K31/42 ,  B41F11/00 ,  A61K39/39 ,  A61K45/06 ,  A61K31/426 ,  A61K38/21 ,  A61K38/47 ,  B41F7/02 ,  B41F7/06 ,  B41F7/08 ,  B41F9/02 ,  B41F13/18 ,  B41F13/193 ,  A61K39/00

摘要： The invention provides for the use of pharmaceutical compositions comprising a thiazolide in the stimulation of the immune system in a subject in need thereof, thereby preventing and/or treating viral diseases, cancer and diseases caused by intracellular protozoan infections.

公开(公告)号：US20190321338A1

公开(公告)日：2019-10-24

申请号：US16460161

申请日：2019-07-02

申请人： Romark Laboratories L. C.

发明人： Jean-Francois Rossignol ,  Marc Ayers

IPC分类号： A61K31/426 ,  A61K9/48 ,  A61K9/28 ,  A61K9/20 ,  A61K38/21 ,  A61K31/7056 ,  A61K9/24

摘要： Solid dosage formulations of nitazoxanide or a nitazoxanide analogue are provided that comprise a controlled release portion and an immediate release portion. The pharmaceutical composition is typically in the form of a bilayer solid oral dosage form comprising (a) a first layer comprising a first quantity of nitazoxanide or analogue thereof in a controlled release formulation; and (b) a second layer comprising a second quantity of nitazoxanide or analogue thereof in an immediate release formulation. Method of using the formulations in the treatment of hepatitis C are also provided.